A phase 2a clinical trial of NEO100-01 is continuing to recruit patients with ... Sequencing the novel drug, THIO, with Libtayo tended to be tolerable in patients with non-small cell lung cancer, ...

Therefore, Senhwa will actively pursue licensing possibilities while carefully evaluating CX-4945's potential as a monotherapy or in combination with the second-line immunotherapy Libtayo.

Senhwa Biosciences, Inc. (TPEx: 6492), a new drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and infectious diseases, today announced that the completion ...

All received solnerstotug (3 mg/kg or 15 mg/kg) with Libtayo. Eleven had not yet reached the first ... medical oncologist and Director of Clinical Research at NEXT Oncology - Dallas, and a principal ...

Sensei is conducting a multi-center Phase 1/2 clinical trial to evaluate the safety ... in combination with Regeneron’s PD-1 inhibitor Libtayo ® (cemiplimab) in patients with advanced solid ...

Sensei is conducting a multi-center Phase 1/2 clinical trial to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of solnerstotug as both a monotherapy and in ...

Senhwa Biosciences, Inc., a new drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and infectious diseases, announced that the completion of Clinical Study ...

Dr Israel Lowy, senior vice president of translational and clinical sciences in ... and vice-chair of the Trial Steering Committee, commented: “Libtayo is an important advancement for patients ...

showing efficacy with its BNT111 vaccine candidate in a phase 2 trial in advanced melanoma. The study is looking at the combination of BNT111 with Regeneron's PD-1 inhibitor Libtayo (cemiplimab ...